Loading...
XKRX
099190
Market cap279mUSD
Jul 10, Last price  
15,220.00KRW
1D
-0.65%
1Q
-23.48%
Jan 2017
3.54%
IPO
73.61%
Name

I Sens Inc

Chart & Performance

D1W1MN
XKRX:099190 chart
P/E
—
P/S
1.32
EPS
—
Div Yield, %
0.65%
Shrs. gr., 5y
0.29%
Rev. gr., 5y
9.16%
Revenues
315.67b
+8.43%
66,549,430,00082,862,590,00095,608,058,000101,920,703,000132,468,197,000156,963,801,000172,996,579,000189,844,257,000203,707,641,000232,934,791,000264,837,131,000265,120,260,000291,137,904,000315,674,763,000
Net income
-5.15b
L+187.00%
8,744,728,00018,641,928,00014,466,160,00014,715,903,00017,560,919,00015,730,466,00022,619,254,00023,425,872,00026,838,558,00025,451,013,00016,138,019,0003,709,063,000-1,794,054,000-5,148,915,000
CFO
20.12b
-12.36%
5,102,430,35016,190,153,21017,845,210,70020,400,604,58912,065,120,82622,247,810,24419,508,172,13937,950,912,00034,614,942,00017,223,811,0006,653,469,00013,045,087,00022,958,071,00020,119,709,000
Dividend
Dec 29, 2025100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Based in South Korea, i-SENS, Inc. specializes in the provision of diagnostic biosensor technology. Its product portfolio encompasses a range of point-of-care (POC) testing equipment, including analyzers for HbA1c, blood gas, electrolytes, and PT/INR. Additionally, the company supplies the CareSens line of blood glucose monitors, along with lancing and various complementary medical devices, and offers diabetes management services. The firm's solutions are distributed internationally, reaching approximately 110 nations, notably across the United States, Japan, and European markets. Established in 2000, i-SENS, Inc. maintains its corporate headquarters in Seoul, South Korea.
URL
https://i-sens.co.kr/
IPO date
Jan 30, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT